Bringing Aberrant Proteins Back into the Fold
from RARECast
In some diseases, such as lysosomal storage disorders, proteins are unable to serve their normal functions because they become misfolded. While some approaches, such as enzyme replacement therapies, have been used to treat these conditions, they can have significant limitations. Gain Therapeutics has developed a platform for using small molecule therapies to return proteins to their proper shape and restore their function. We spoke to Eric Richman, CEO of Gain Therapeutics, about its platform technology, how it works, and why it offers a compelling alternative to other approaches to treating lysosomal storage disorders.
Embed this episode
What this episode covers
Eric Richman, CEO of Gain Therapeutics, discusses its platform technology, how it works, and why it offers a compelling alternative to other approaches to treating lysosomal storage disorders.
No transcript yet.